Bristol's Orzel Will Be Reviewed By FDA Oncologics Cmte. In September
Executive Summary
Bristol-Myers Squibb's colorectal cancer therapy Orzel (UFT/leucovorin) is slated for review in September by FDA's Oncologic Drugs Advisory Committee, Bristol CFO Michael Mee said during a July 21 teleconference discussing the firm's second quarter results.